COMydAL Program

We are excited to welcome you to participate in the 1st World Congress on Controversies in MDS and AML (COMydAL), which will be held virtually over the days of September 22-23, 2022, in parallel with the 2022 IACH Meeting.

This inaugural program will bring to the forefront the latest and most controversial date and information in the field of MDS and AML, providing a unique opportunity for world-class leaders in the field to debate vital issues – thank you for joining!

DAY 1 – AML
Thursday, September 22, 2022
Co-chairs: Amer Zeidan, USA and Andrew Wei, Australia
13:15-13:30 Welcome Address
13:30-14:30 Session 1
Debate: Therapeutic decisions based on MRD in AML: Ready for prime time?
13:30-13:45 Yes: Christopher Hourigan, USA
13:45-14:00 No: Christopher Gibson, USA
14:00-14:15 Case studies of MRD use for therapeutic decisions in AML: Andrew Wei, Australia
14:15-14:30 Panel discussion
14:30-15:30 Session 2
Debate: Which FLT3 inhibitor to use in frontline therapy in FLT3 mutated AML?
14:30-14:45 Midostaurin: Richard Stone, USA
14:45-15:00 Quizartinib: Harry Erba, USA
15:00-15:15 Case studies of FLT3 inhibitors in AML: Selina Luger, USA
15:15-15:30 Panel discussion
15:30-16:30 Session 3
Debate: Intensive chemotherapy or Ven-based lower intensity regimens for older FIT AML patients?
15:30-15:45 Intensive chemo: Jessica Altman, USA
15:45-16:00 Non-intensive chemo: Nicholas Short, USA
16:00-16:15 Case studies: Can we cease VEN-AZA in patients in long-term remission? Chong Chyn Chua, Australia
16:15-16:30 Panel discussion
16:30-17:30 Session 4
Debate: Should we use maintenance therapy post allogeneic transplant in AML?
16:30-16:45 Yes: Lohith Gowda, USA
16:45-17:00 No: Catherine Lai, USA
17:00-17:15 Case studies of how I use maintenance therapies post alloBMT in AML: TBA
17:15-17:30 Panel discussion
17:30-18:30 Session 5
17:30-17:45 Will immune checkpoint inhibition find a way in AML and MDS? Naval Daver, USA
17:45-18:00 Will CAR therapies find a way in AML and MDS? Monica Guzman, USA
18:00-18:15 Case studies: How I use immune therapies in AML and MDS: Ivana Gojo, USA
18:15-18:30 Panel discussion
18:30-19:30 Session 6
Debate: In 10 years we will cure most AML patients without transplant
18:30-18:45 Yes: Tapan Kadia, USA
18:45-19:00 No: Gail Roboz, USA
19:00-19:15 Case studies: How I decide on recommending alloBMT in AML: Michael Heuser, Germany
19:15-19:30 Panel discussion
DAY 2 – MDS
Friday, September 23, 2022
Co-chairs: Amer Zeidan, USA and Valeria Santini, Italy
11:00-12:00 Session 7
Debate: Are we ready for clinical trials with triplets in HR-MDS?
11:00-11:15 Yes: Uwe Platzbecker, Germany
11:15-11:30 No: TBA
11:30-11:45 Case studies: When do I use combination therapy in HR-MDS in my clinic? Amy DeZern, USA
11:45-12:00 Panel discussion
12:00-13:00 Session 8
Debate: Overall survival should be the basis of any approval in HR-MDS
12:00-12:15 Yes: Uma Borate, USA
12:15-12:30 No: Amy DeZern, USA
12:30-12:45 Case studies: How do I use “less than CR” responses in HR-MDS in my clinic to direct therapy: Anne Sophie Kubasch, Germany
12:45-13:00 Panel discussion
13:00-14:00 Session 9
Debate: Can observation be a good choice in some cases of higher risk MDS?
13:00-13:15 Yes: Valeria Santini, Italy
13:15-13:30 No: Pierre Fenaux, France
13:30-13:45 Case studies: How do I use observation in management of lower and higher risk MDS? Elizabeth Griffiths, USA
13:45-14:00 Panel discussion
Program pause
16:00-17:00 Session 10
Debate: Should we give HMA before alloBMT for HR-MDS with 5-9% blasts?
16:00-16:15 Yes: Maximilian Stahl, USA
16:15-16:30 No: Emanuele Angelucci, Italy
16:30-16:45 Case studies: bridging therapy choices before alloBMT in HR-MDS: Hetty Carraway, USA
16:45-17:00 Panel discussion
17:00-18:00 Session 11
Debate: The primary risk stratification tool in MDS should become IPSS-M
17:00-17:15 Yes: Rafael Bejar, USA
17:15-17:30 No: Aziz Nazha, USA
17:30-17:45 Case studies: How do I use the different MDS stratification tools in my clinic: Aditi Shastri, USA
17:45-18:00 Panel discussion
18:00-19:00 Session 12
Debate: Why do we keep having failed phase 3 trials in HR-MDS?
18:00-18:15 Bad drugs: Steven Gore, USA
18:15-18:30 Bad trial designs: Mikkael Sekeres, USA
18:30-18:45 Overview of exciting drugs in lower and higher risk MDS: Amer Zeidan, USA
18:45-19:00 Panel discussion
19:00-19:15 Closing Remarks